Research & Publications

Translational research has always been the linchpin of Lifedoc’s clinical framework, further enabling us to provide healthcare that is quality-oriented and data-driven. Over the last 15 years, research has remained an integral part of our efforts to maximize the applicability of health data. With active participation in industry-sponsored and investigator-initiated research, we aim to to inform emerging treatments and continually refine our clinical model for the ultimate benefit of the patient. This focus allows us to continually develop data to support our evidence-based approach, ensuring that our patients receive the most effective healthcare and clinical interventions. Ultimately, this allows us to fulfill our mission of establishing Lifedoc as a reference model for researchers and practitioners studying the development and prevention of cardiometabolic conditions.

Take a look at our past and ongoing trials, research partnerships as well as some of our published/presented studies below.

Interested in working with our research site? Contact us.

Quality care for all. A kid playing doctor.

Research Partnerships

Novo Nordisk

Industry-sponsored Clinical Trials

Ongoing Trials

– Boehringer-Ingleheim – Safety and Efficacy of SGLT-2 and DPP-4 in Type 2 Diabetes, Children 10 – 17 years of age.

Past Trials

– Janssen – Safety and Efficacy of SGLT-2  in Type 2 Diabetes, Adults – Recognized as Highest Recruiting/Retaining Site in the US

– Novo Nordisk – Safety and Efficacy of Liraglutide in Overweight and Obesity, Children and Adolescents 10-17 years of age – Recruited First and Second Patient Globally

–  Novo Nordisk – Safety and Efficacy of Liraglutide and Metformin in Type 2 Diabetes, Children and Adolescents 10-17 years of age – Recognized as Highest Recruiting Site in the US

Notable Publications

Published: American Journal of Nephrology
Authors: Meg J Jardine 1 2 , Kenneth W Mahaffey 3 , Bruce Neal 1 4 5 6 , Rajiv Agarwal 7 , George L Bakris 8 , Barry M Brenner 9 , Scott Bull 10 , Christopher P Cannon 11 , David M Charytan 12 , Dick de Zeeuw 13 , Robert Edwards 10 , Tom Greene 14 , Hiddo J L Heerspink 13 , Adeera Levin 15 , Carol Pollock 16 , David C Wheeler 17 , John Xie 10 , Hong Zhang 18 , Bernard Zinman 19 , Mehul Desai 10 , Vlado Perkovic 1 , CREDENCE study investigators
People with diabetes and kidney disease have a high risk of cardiovascular events and progression of kidney disease. Sodium glucose co-transporter 2 inhibitors lower plasma glucose by reducing the uptake of filtered glucose in the kidney tubule, leading to increased urinary glucose excretion.
Published: Pan American Journal of Public Health
Authors: Patricio López-Jaramillo 1 , Ramfis E Nieto-Martínez 2 , Gestne Aure-Fariñez 3 , Carlos O Mendivil 4 , Rodolfo A Lahsen 5 , Ruy L Silva-Filho 6 , Luiz A Andreotti 7 , Mónica E Manrique 8 , Miguel A Pasquel-Andrade 9 , Ignacio Rangel 10 , Maricela Vidrio 11 , Rutila Castañeda 12 , Manuela Restrepo 13 , Miguel E Pinto 14
To understand the status of prediabetes diagnosis and treatment in Latin America and to evaluate the use of metformin for diabetes prevention in this context.
Published: The Lancet
Authors: NCD Risk Factor Collaboration (NCD-RisC)
Underweight, overweight, and obesity in childhood and adolescence are associated with adverse health consequences throughout the life-course. Our aim was to estimate worldwide trends in mean body-mass index (BMI) and a comprehensive set of BMI categories that cover underweight to obesity in children and adolescents, and to compare trends with those of adults.
Published: Current Diabetes Reports
Authors: Ramfis Nieto-Martínez 1 2 3 , Juan P González-Rivas 4 , José R Medina-Inojosa 5 , Hermes Florez 6 7
Eating disorders (ED) affect energy intake modifying body fat depots. Prior evidence suggests that binge eating disorder (BED) and bulimia nervosa (BN) could increase the risk for type 2 diabetes (T2D), while anorexia nervosa (AN) could reduce it.
Published: Annals of Global Health
Authors: Ramfis Nieto-Martínez 1 , Juan P González-Rivas 2 , Pablo Aschner 3 , Noël C Barengo 4 , Jeffrey I Mechanick 5
Type 2 diabetes (T2D) imposes a heavy burden in developing countries, requiring effective primary prevention policies. Randomized clinical trials have identified successful strategies in T2D prevention. However, translating these results to real-life scenarios and adapting to ethnocultural differences is a major challenge.
1 3 4 5 6 7 12

Contact Us